Clinical Trials Logo

HIV-1 Infection clinical trials

View clinical trials related to HIV-1 Infection.

Filter by:

NCT ID: NCT03493568 Recruiting - HIV-1-infection Clinical Trials

Switch From Dual Regimens Based on Dolutegravir Plus a Reverse Transcriptase Inhibitor to E/C/F/TAF in Virologically Suppressed, HIV-1 Infected Patients (Be-OnE)

Be-OnE
Start date: February 6, 2017
Phase: Phase 3
Study type: Interventional

Research hypothesis: Switching from dual regimens based on dolutegravir plus a RTI to a single tablet regimen of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), lowers the exposure to Residual Viremia (and hence the risk of viral rebound), without increasing treatment toxicity.

NCT ID: NCT03478540 Recruiting - HIV-1-infection Clinical Trials

Gut Microbiota and Immune Recovery

Start date: December 1, 2017
Phase:
Study type: Observational

To explore whether gut microbiota would impact CD4 T cells recovery in HIV-infected patients on antiretroviral therapy (ART). We prospectively enroll patients initiate ART and collect their fecal at followup for one year.

NCT ID: NCT03472326 Recruiting - HIV-1-infection Clinical Trials

Efficacy of GS-9131 Functional Monotherapy in HIV-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen

Start date: April 3, 2018
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to evaluate the short-term antiviral potency of a regimen containing GS-9131 at 30 mg, 60 mg, and 90 mg, compared to placebo-to-match (PTM) GS-9131, each administered once daily with the existing failing antiretroviral therapy (ART) regimen. This is a two-part study. Part 1 consists of two cohorts: a Sentinel Cohort followed by a Randomized Cohort. Eligible participants from Part 1 will proceed to Part 2 followed by an optional open-label extension.

NCT ID: NCT03426189 Recruiting - HIV-1-infection Clinical Trials

HIV Persistence in Lymph Node and Peripheral Blood

HIV-PRADA
Start date: January 2, 2017
Phase: N/A
Study type: Observational

The aim of this project is to determine whether latent HIV is enriched in cells expressing certain proteins (receptors) on their surface and whether it is possible to eliminate these cells through the use of drugs that specifically target these proteins. Lymph nodes are known to contain very high numbers of HIV infected cells.

NCT ID: NCT03416790 Not yet recruiting - HIV-1-infection Clinical Trials

IMPAACT 2015 - Evaluation of the HIV-1 Reservoir in the Central Nervous System of Perinatally-Infected Youth and Young Adults With Cognitive Impairment

Start date: March 2018
Phase: N/A
Study type: Observational

IMPAACT 2015 is a cross-sectional, exploratory study that will investigate the central nervous system (CNS) reservoir in perinatally HIV-infected adolescents and young adults on effective antiretroviral therapy with neurocognitive impairment. The study will assess the frequency with which HIV is detected in the cerebral spinal fluid (CSF) in this population and assess whether detectable HIV in the CSF correlates with markers of inflammation and neuronal injury. Findings from this study will advance understanding of the role of the CNS in HIV-1 persistence and its implications for future HIV-1 remission research.

NCT ID: NCT03405935 Recruiting - HIV-1-infection Clinical Trials

A Study to Evaluate Switching From an E/C/F/TAF FDC Regimen or a TDF Containing Regimen to B/F/TAF FDC in HIV-1 Infected Adults

Start date: March 1, 2018
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to characterize the virologic efficacy of switching virologically suppressed participants on an elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) regimen or a tenofovir disoproxil fumarate (TDF) containing regimen to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) FDC.

NCT ID: NCT03399903 Recruiting - HIV-1-infection Clinical Trials

Study of Pentasa® for Reducing Residual Systemic Immune Activation in Treated HIV Infection

Start date: May 1, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

An open label study will be performed on 60 people with HIV infection who are maintained on effective treatment with antiretroviral drugs.

NCT ID: NCT03399136 Completed - Aging Clinical Trials

Fitness and Longevity in Exercise

FLEX
Start date: July 19, 2007
Phase: N/A
Study type: Interventional

The study objective was to determine the safety and efficacy of aerobic exercise in older HIV-infected men in a randomized trial comparing different levels of exercise intensity.

NCT ID: NCT03392805 Recruiting - HIV-1-infection Clinical Trials

Infectious Diseases and Movement Program: Study of the Effects of Physical Activity on HIV Infection

PRIMO
Start date: January 1, 2016
Phase: N/A
Study type: Interventional

exercise and physical activity can have an anti-inflammatory effect, while there is evidence that a sedentary lifestyle could be the basis for the development of systemic inflammation and increased cardiovascular risk. The primary objective is to assess whether regular physical activity is able to induce a decrease in systemic immune-activation in HIV positive patients.

NCT ID: NCT03360682 Not yet recruiting - HIV-1-infection Clinical Trials

Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV‐1‐Infected Solid Organ Transplant Patients

Start date: January 2018
Phase: Phase 4
Study type: Interventional

The aims of this study are to obtain pharmacokinetic data on interactions between dolutegravir (DTG) and immunosuppressant drugs (Cyclosporine A, Tacrolimus, Sirolimus and Mycophenolic acid) in solid organ transplant (SOT) recipients to provide proof of principle data that DTG plus 2 nucleosides (NUCs) is safe and effective in HIV-infected SOT recipients.